glyburide; glibenclamide (Micronase, DiaBeta, Glynase)

From Aaushi
Jump to navigation Jump to search

Introduction

Tradename: Micronase, DiaBeta. 2nd generation sulfonylurea.

Indications

Contraindications

pregnancy category = b

safety in lactation = ?

Dosage

start with 2.5-5 mg PO QD, max 20 mg/day, QD or divided BID

Geriatric patients:

Tabs: 1.25, 2.5, 5 mg.

Micronized glyburide. Tradename: Glynase Press Tab.

Pharmacokinetics

elimination via liver

elimination via kidney

1/2life = 10 hours

Adverse effects

Drug interactions

Laboratory

Mechanism of action

More general terms

Component of

References

  1. The Pharmacological Basis of Therapeutics, 9th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1996
  2. 2.0 2.1 2.2 Kaiser Permanente Northern California Regional Drug Formulary, 1998
  3. 3.0 3.1 3.2 Drug Information & Medication Formulary, Veterans Affairs, Central California Health Care System, 1st ed., Ravnan et al eds, 1998
  4. 4.0 4.1 4.2 Prescriber's Letter 7(12):71 2000 Journal Watch 20(24):192, 2000 Langer et al, N Engl J Med 343:1134, 2000
  5. Geriatric Dosage Handbook, 6th edition, Selma et al eds, Lexi-Comp, Cleveland, 2001
  6. 6.0 6.1 6.2 Drug Evaluation Monograph, Micromedex
  7. 7.0 7.1 Ryberg T et al, Diabetes Car 17(9): 1026, 1994 PMID: https://www.ncbi.nlm.nih.gov/pubmed/95079919
  8. 8.0 8.1 Paauw DS Dangerous and Deadly Drug Combinations Medscape. June 30, 2016 http://www.medscape.com/features/slideshow/dangerous-drug-combinations
  9. 9.0 9.1 van Dalem J et al Risk of hypoglycaemia in users of sulphonylureas compared with metformin in relation to renal function and sulphonylurea metabolite group: population based cohort study. BMJ 2016;354:i3625 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/27413017 Free full text <Internet> http://www.bmj.com/content/354/bmj.i3625

Database